PMN is trading at $13.86 (5.3% up) as fresh bullish analyst attention and significant price target hikes drive investor optimism.
- Cantor Fitzgerald recently issued an Overweight rating, reinforcing a Strong Buy consensus for the stock.
- Market sentiment is being bolstered by the company’s Alzheimer’s program and anticipation of upcoming clinical trial data.
- The positive coverage has fueled continued upside momentum for the stock in after-hours trading.